Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016

  • ID: 3802759
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Egis Gyogyszergyar Nyrt
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • TearSolutions, LLC.
  • MORE
Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016

Summary

‘Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Review, H1 2016’, provides in depth analysis on Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2)
- The report reviews Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Egis Gyogyszergyar Nyrt
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • TearSolutions, LLC.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) Overview

Therapeutics Development

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Products under Development by Stage of Development

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Products under Development by Therapy Area

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Products under Development by Indication

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Products under Development by Companies

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Companies Involved in Therapeutics Development

Egis Gyogyszergyar Nyrt

Johnson & Johnson

Otsuka Holdings Co., Ltd.

SK Biopharmaceuticals Co., Ltd.

TearSolutions, LLC.

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Drug Profiles

brexpiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Egis-11150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lacripep - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORM-12741 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-PSY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Dormant Projects

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Discontinued Products

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) - Featured News & Press Releases

May 16, 2016: Otsuka to Present Data on Brexpiprazole at American Psychiatric Association Annual Meeting

Feb 08, 2016: U.S. FDA Accepts for Review Otsuka and Lundbeck’s sNDA Filing for Labeling Update of REXULTI (Brexpiprazole) for Maintenance Treatment of Schizophrenia

Jul 11, 2015: FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia

May 12, 2015: Otsuka and Lundbeck to Present Data on Investigational Compound Brexpiprazole in Schizophrenia and Major Depressive Disorder at American Psychiatric Association Annual Meeting

Apr 17, 2015: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry

Dec 11, 2014: Otsuka And Lundbeck's Brexpiprazole Demonstrates Statistically Significant Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting

Dec 10, 2014: Otsuka And Lundbeck Present Phase III Data on Brexpiprazple As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting

Sep 24, 2014: U.S. FDA Accepts Otsuka and Lundbeck's Filing for Review of Brexpiprazole for the Treatment of Schizophrenia and as Adjunctive Therapy for the Treatment of Major Depression

Jul 14, 2014: Otsuka and Lundbeck Submit New Drug Application in The Us for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder

Mar 03, 2014: Investigational compound Brexpiprazole met primary and secondary study endpoints in phase III clinical trial in major depressive disorder

Jan 24, 2014: Otsuka and Lundbeck to Present New Data on Brexpiprazole in Major Depressive Disorder at European Psychiatry Association 2014 Congress

Mar 21, 2013: Orion Presents Promising Phase II Data For New Alzheimer's Disease Drug At AAN Annual Meeting

Mar 11, 2013: New Add-On Drug May Improve Memory In People With Moderate Alzheimer's Disease, Study Shows

May 15, 2011: Otsuka Pharmaceutical Announces Results From Phase II Study Of Investigational Product OPC-34712 As Adjunctive Therapy In Adults With Major Depressive Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 53List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Egis Gyogyszergyar Nyrt, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Otsuka Holdings Co., Ltd., H1 2016

Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Pipeline by TearSolutions, LLC., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 38List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Egis Gyogyszergyar Nyrt
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • TearSolutions, LLC.
  • MORE
Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The author's latest report Alpha-2C Adrenergic Receptor - Pipeline Review, H1 2016, outlays comprehensive information on the Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively.

Furthermore, this report also reviews key players involved in Alpha-2C Adrenergic Receptor (Alpha-2 Adrenergic Receptor Subtype C4 or Alpha-2C Adrenoreceptor or ADRA2C or ADRA2RL2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Egis Gyogyszergyar Nyrt
Johnson & Johnson
Otsuka Holdings Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
TearSolutions, LLC.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll